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Summary Interleukin (IL) 15 is a novel cytokine with IL-2-like activity. In this study, we examined the effect of IL-15 on induction of non major
histocompatability complex (MHC)-restricted killeractivity and of type 2 cytokine production by peripheral blood and pleural mononuclear cells
(MNCs), from 34 lung cancer patients and 20 control subjects. IL-15 induced significant killeractivity in blood MNCs from lung cancer patients
as well as control subjects against a small-cell lung cancer cell line (SBC-3). Effective killer induction by IL-15 was observed even in blood
MNCs and pleural MNCs from the site of tumourgrowth in advanced lung cancer patients. IL-12 had an additive effect with a suboptimal dose
of IL-15 in induction of killer activity. In the case of MNCs from lung cancer patients, IL-10 production was more prominent when cells were
incubated with IL-2 than with IL-15. IL-5 production was observed in MNCs from lung cancer patients stimulated with IL-2, but not with IL-15.
These observations suggest that IL-15, by virtue of its lesser induction of type 2 cytokine, may be a better candidate than IL-2 for lung cancer
immunotherapy.
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Interleukin 15(IL-15) is a novel M 15 000 cmtokine and has similar
biological activities to those of IL-2: it induces T-cell proliferation.
enhances natural killer (NK) cell cytotoxicity and up-regulates
production of NK cell-derived cytokines (Carson et al. 1994).
Recently. attention has been focused on the clinical application of
IL-15 for cancer immunotherapy (Gamero et al. 1995) and. for
effective clinical application ofIL-15. at least two problems must be
solved. We have already demonstrated that the presence ofa malig-
nant neoplasm affects various host functions (Sone et al. 1990:
Nabioullin et al. 1995). Therefore. the first problem is whether the
presence of lung cancer affects the induction of non-major histo-
compatibility complex (MHC)-restricted killer activity by 1L-15.
The second problem is to evaluate type 2 cytokine production
by IL-15-activated mononuclear cells (MNCs). because the
growth of cancer cells is regulated by the cytokine network. via
autocrine and paracrine pathways. in situ. In the analysis of the
cytokine network. two distinct cytokine patterns generated by T
lymphocytes can be considered (Mosmann et al. 1986: Romagnani
et al. 1991: Salgame et al. 1991). Type 2 lymphocytes produce IL-
4. 11L-5 and IL-10 and suppress the cellular immune response.
whereas type 1 lymphocytes produce 11L-2 and IFN-yand promote
the cellular immune response (Paul and Seder. 1994). Several
reports have demonstrated that type 2 cytokine expression is
predominant at the tumour growing site and that these cytokines
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may mediate immunosuppression (Yamamura et al. 1993:
Kharkvitch et al. 1994). Production of type 2 cytokines by lung
cancer has been reported (Hung et al. 1995). and immunotherapy
with cytokines may alter this type 2 predominant pattern of the
type 1/type 2 axis.
In this work. we studied the effect of L-15 alone or in combina-
tion with L-12 on the immune function of MNCs from lung
cancer patients. in terms of expression of non-MHC-restricted
killer activity and type 2 cytokine production.
MATERIALS AND METHODS
Patients with lung cancer and control patients
Thirty-four patients with primary lung cancer were studied after
obtaining informed consent. Of these. 24 were men and ten were
women aged 36-83 years (median age 67 years). Histological
examinations revealed that 17 patients had adenocarcinoma. nine
had squamous cell carcinoma. five had small-cell carcinoma and
three had large-cell carcinoma. Staging examination revealed that
17 patients were stage IV. ten were stage IIIB. four were stage
I11A. two were stage H and one was stage I. Nine patients had
malignant pleural effusion. They had received no anti-cancer
therapy before this study. Twenty subjects were studied as
controls. Ofthese. nine subjects were control patients (three males
and six females) aged 22-82 years (median age 42 years).
Examinations revealed no malignant lesions or autoimmune
diseases in these nine patients. The other 11 control subjects (nine
men and two women) were healthy volunteers who had no signs of
infection. were not taking medication and were aged 22-48 years
(median age 28 years). They all gave informed consent to
participate in the experiments.
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Figure 1 Effect of a combination of IL-15 and IL-12 on inducon of killer
activity in peripheral blood MNCs from lung cancer patients. Peripheral blood
MNCs (1 x 105 per well) from lung cancer patients were incubated in medium
with or without 5 ng ml-' IL-15 or 5 U ml-' IL-2 in the presence or absence of
a suboptimal (1 U ml-') concentraton of IL-12 (A) and 50 ng ml-' IL-15 or
500 U ml-' IL-2 in the presence or absence of an optimal (100 U ml-')
concentration of IL-12 (B) for 4 days. Then their Wkler activities against SBC-
3 cells were measured at an E/T ratio of 10. Columns and bars show means
± s.e.s. Asterisks indicate significant differences from values in medium alone
(OP < 0.05, "*P < 0.01). NS, not significant
Reagents
Recombinant human IL-15 was obtained from PeproTech (Rocky
Hill, NJ. USA). Recombinant human IL-12 (specific activity 5.26
x 106U mg-' protein) was supplied by the Genetics Institute
(Cambridge. MA. USA) and recombinant human IL-2 (specific
activity 1.14 x 10- U mg-1 protein. as assayed on IL-2-dependent
munne NKC3 cells) was a gift from Takeda Pharmaceutical
(Osaka. Japan). None of these materials contained endotoxins. as
judged by Limulus amebocyte assay (sensitivity limit. 0.1 ng ml-'.
Seikagaku Kogyo. Tokyo. Japan).
Table 1 Killer activites of peripheral blood MNCs and pleural MNCs from
lung cancer patients at different clinical stages
Cytotoxicity against SBC-3 cells (%)
MNCs Medium IL-15 IL-2
(50 ng ml-') (500 U ml-')
Set1
Contro subjects (n = 20) 1.6 0.4a 35.1 ± 4.3- 30.8 ±4.5-
Lung cancer patients (n = 34) 4.0 + 0.8 40.0 ± 4.8- 40.7 ± 4.5**
Stage 1-II1B (n = 17) 5.0 1.3 44.1 ± 6.8*" 45.3 ± 6.3-
Stage IV (n = 17) 3.0 1.0 36.0 ±6.99 36.1 ±6.5"
Set2
Peripheral blood (n = 9) 1.2 0.6 20.8 ±5.9* 23.1 ± 6.5*
Pleural (n = 9) 2.7 _ 0.6 33.0 ± 7.5- 31.2 ±7.3'
aValues are expressed as means + s.e.m. and Significantly different from
the value without cytokines ('P < 0.05. UP < 0.01).
71)
Grand Island. NY. USA) and gentamicin (Schering-Plough.
Osaka Japan). designated complete RPMI-1I40 (CRPMI)
medium. at 370C in a humidified atmosphere containing 5%
NS carbon dioxide. Forcytotoxicity assays. cultured target cells were
used in the exponential growth phase.
Isolation of peripheral blood mononuclear cells and
pleural mononuclear cells and cytotoxicity assay
Peripheral blood MNCs and pleural MNCs were separated from
heparinized venous blood and pleural effusion. respectively. as
described previously (Sone et al. 1987: Yanagawa et al. 1989). The
resultant MNCs (105 per well) were incubated in CRPMI-1640.
with or without 10 U mFl or 100 U ml-1 IL-12. in the presence or
absence of5 ng ml-1 or 50 ng mlF IL-15 or 5 U mlF or 500 U mlF
IL-2. at 370C under a humidified atmosphere containing 5%
carbon dioxide. These concentrations of IL-2. IL-12 and IL-15
were chosen as suboptimal and optimal concentrations to augment
killer activity mediated by MNCs as described previously
(Nabioullin et al. 1994: Takeuchi et al. 1996). After incubation for
4 days. the culture supernatants were collected after briefcentrifu-
gations and the cell-mediated cytotoxicity was assayed against
SBC-3 cells by measuring 5ICr release in a 4-h test as described
previously (Sone et al. 1987).
Quantitative measurements of cytokines
IL-S. IL-10 and granulocyte-macrophage colony-stimulating
factor (GM-CSF) were measured by enzyme immunoassay (EIA)
essentially as described previously (Takeuchi et al. 1996). The
sensitivity limits ofall these ELAs were 20 pg ml-'.
Cell lines
A human lung small-cell cancer line (SBC-3) was kindly provided
by Dr Hiraki (Okayama University. Okayama. Japan) (Yonei et al.
1993). The cells were maintained by culture in RPMI-1640
medium (Nissui Pharmaceutical. Tokyo, Japan) supplemented
with 10% heat-inactivated fetal bovine serum (FBS) (Gibco.
Statistical analysis
The statistical significance of differences between groups were
analysed by Student's t-test (two-tailed). Wilcoxon single-rank test
(paired two groups) or Mann-Whitney U-test (unpaired two
groups). Probability values of less than 0.05 were considered
significant.
Britsh Joumal ofCancer (1998) 78(5), 616-620
I
-
NS
I
- NS
i
I r-
0 CancerResearch Campaign 1998618 E Takeuchietal
Medium
m
.-
E
cob
-j 0.
Medium
80
60'
40.
2I
Medium IL-15 IL-2
(n=14) (n=14) (n=14)
IL-12
I
[a
Chu~im 11A-19;
m I
Mewkum IL-1
(n=l1) (n=ii)
Mediun
E
U-
0
IL-'
(n=1l)
IL-12
80
60
40'
(inU1i IL- Ia 4L)E
(n=14) (n=14) (n=14)
m
a
IL C.
(I)
0
I en 11 -1 fi ni (UII IL-ID
(n=11) (n=11) (n=11)
IL-12
Medium IL-15 IL-2
(n=21) (n=21) (n=8)
Figure 2 Iniucbton by IL-15 of cytolne producion by peripheral blood MNCs from lung cancer paents. Per al blood MNCs (1 x l05 perwell) from iung
cancer patients were incubated in meun with or without 50 ng ml- of IL-15 or 500 U ml-' of IL-2 in the presence or absence of an optimal (100 U ml-1)
concntration of IL-12. After incubation for 4 days, Fe culture supematants were collected after brief centrifugations. IL-10, IL-5 and GM-CSF were measured
by ElA Ckolm and bars show means ± s.e.s. Asterisks indicate signiicant differences from values in IL-1i5 (P< 0.01)
RESULTS
Effect of IL-15 on killer induction of peripheral blood
MNCs andpleural MNCs from lung cancer ants
We first examined the effects of 1L-2 and 11-15 on non-MHC-
restricted killer induction in peripheral blood MNCs from lung
cancer patients. Blood MNCs were separated from venous blood
oflung cancer patients (n = 34) and control subjects (n = 20) and
incubated with orwithoutthe optimal doseof11-15 (50 ngml-') or
1L-2 (500 U ml-') for 4 days. Then their killer activities, against a
lung cancer cell line (SBC-3). were measured at an effector to
target (EJM) ratio of 10. The results are shown in Table 1. MNCs
(I x l0I per well), cultured in medium alone, exhibited only
marginal cytotoxicity against SBC-3 cells. On the other hand, U1-
15 was as effective as 11-2 at inducing killer activity on MNCs
from lung cancer patients, as well as from control subjects.
Next. to examine the influence of tumour progression on killer
induction, the 11-15-induced killer activities ofblood MNCs were
evaluated inlung cancerpatients without clinical distant metastases
(stage I-flB) and with clinical distant metastases (stage IV). The
1L-15-induced cytotoxicity against SBC-3 cells was alittle lowerin
cells from patients with distant metastasis (n = 17) than in those
without distant metastasis (n = 17), but the difference was not
statistically significant. There was nodifferencebetweenthe 1L-15-
and 1L-2-induced killer activities against SBC-3 cells ofcells from
stage I-MB lung cancerpatients or stage IV lung cancerpatients.
To investigate the effect of 1L-15 on killer induction in the
tumour growing site, we examined the effect of IL-15 on killer
induction by MNCs in the malignant pleural effusion from the
tumourgrowth site. Pleural andblood MNCs wereobtained simul-
taneously from the same patients (n = 9) and their cytotoxicities
against SBC-3 cells were examined after incubation with or
without the optimal dose of 1L-15 or IL-2 for 4 days. The results
are shown in Table 1. Pleural and blood MNCs showed low cyto-
toxicity when cultured in medium alone. There was no difference
in the killer activities induced by the optimal concentration of IL-
15 or IL-2 of MNCs from malignant pleural effusions or from
peripheral blood.
Effects of ombinaons oflL-15 orlL-2 with IL-12 on
killer induction of peripheral blood MNCs of lung
cancer paPtdits
We examined the effects of combinations of suboptimal
(5 ng ml-') and optimal (50 ng ml-') concentrations of 1L-15 on
non-MHC-restricted killer induction by IL-12 in cells from lung
cancer patients (n = 16). L-12 had an additive effect with subop-
timal concentrations of 1L-15 and 1L-2 on induction of killer
activity against SBC-3 cells (Figure IA). In contrast, 1L-12 had no
additive effect with optimal concentrations of IL-15 or 1L-2 on
induction ofkilleractivity against SBC-3 cells (Figure IB).
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IL-15 induction of cytokine production by peripheral
blood MNCs from lung cancer patients
IL-1O production was examined in 14 lung cancer patients and
eight control subjects. In control subjects, the presence of 1L-12
was necessary to induce IL-10 production by IL-2-stimulated
MNCs (48.5 ± 22.4 pg ml-') and IL-15-stimulated MNC
(19.6 ± 6.4 pg ml-'). In lung cancer patients. 1L-10 production was
greater when cells were incubated with 1L-2 than with 1-15 alone
or in combination with 11-12 (Figure 2).
1L-5 production was examined in 11 lung cancer patients and
ten control subjects. 11-15. as well as 11L-2. alone or in combina-
tion with IL-12, induced no IL-5 production in the culture super-
natant ofMNCs from control subjects (data not shown). As shown
in Figure 2, IL-2. alone or in combination with IL-12. induced
significant production of1L-5 by MNCs from lung cancer patients.
Conversely, noproduction was observed in culture supernatants of
MNCs from lung cancer patients incubated with 1L-15 alone or in
combination with IL-12 (Figure 2).
GM-CSF production was examined in 23 lung cancer patients
and nine control subjects. In control subjects. there was no differ-
ence in the production of GM-CSF by 1L-2-stimulated MNCs
(30.3 ± 20.3 pg ml-') and IL-15-stimulated MNCs (not detectable).
In lung cancer patients. there was also no difference in the produc-
tion of GM-CSF by IL-2-stimulated MNCs and 1L-15-stimulated
MNCs (Figure 2).
DISCUSSION
In this study. we showed that 1L-15 is a cytokine with potential
effectiveness in cancer immunotherapy based on the following
findings. First, IL-15 was as effective as 1L-2 in inducing non-
MHC-restricted cytotoxic activity of blood MNCs and pleural
MNCs of lung cancer patients. even at advanced stages. Second.
compared with IL-2. IL-15 was less effective in inducing produc-
tion oftype 2 cytokines such as IL-IO and 1L-5.
It is important to examine whether the presence of malignant
neoplasm affects the killer induction by 11-15. Gamero et al
(1995) reported that lymphocytes ofmetastatic melanoma patients
express killer activity in response to 11-15. Exploring this possi-
bility in lung cancer patients. we have demonstrated in this study
that peripheral blood MNCs from lung cancer patients generated
killeractivity against human lung cancercells (SBC-3) in response
to 1L-15. as well as from control subjects (Table 1). and that IL-15.
like IL-2. induced killer activity in MNCs of lung cancer patients
even with distant metastases (Table 1). Moreover, we found that
MNCs from malignant pleural effusions. where host cells exist in
contact with cancer cells. generated killer activity against human
lung cancer cells (SBC-3) in response to IL-15 (Table 1). In addi-
tion, similar to our earlier report with MNCs from normal volun-
teers (Takeuchi et al. 1996). suboptimal concentrations of IL-15 as
well as IL-2 had additive effects on IL-12-induced killer activity of
MNCs from lung cancer patients against SBC-3 cells (Figure 1).
IL-15 seems to be as effective as IL-2 in inducing killer activity in
lung cancer patients. and combinations of lower doses of the
cytokines IL-15 and 11-12 may reduce their individual adverse
effects at high concentrations.
As the growth ofcancer cells in situ is regulated by the cytokine
network via autocrine and paracrine pathways. it is important to
examine whether the exogenous cytokine affects the cytokine
network in cancer patients in addition to the analysis of its ability
to induce killer cell activity. In the analysis of the cytokine
network, two distinct cytokine patterns generated by T lympho-
cytes can be considered (Mosmann et al. 1986: Romagnani et al.
1991: Salgame et al. 1991). Type 2 lymphocytes produce 11-4. IL-
5 and 1L-10 and suppress the cellular immune response. whereas
type 1 lymphocytes produce IL-2 and IFN-y and promote the
cellular immune response (Paul and Seder. 1994). Recently. it has
been established that type 2 cytokine expression is predominant at
the tumour site, including lung cancer (Yamamura et al. 1993:
Smith et al. 1994: Hung et al. 1995). in the tumour-infiltrating
lymphocytes (Kharkevitch et al, 1994) and peripheral blood of
cancer patients (Pellegrini et al. 1996). Therefore, we examined
type 2 cytokine production by 1L-15-activated MNCs from lung
cancer patients in this study.
Although the clinical relevance of type 2 cytokines to tumour
progression is not fully elucidated in human cancer. 1L-10 is consid-
ered to be an immunosuppressive factor because of its inhibitory
effect on antigen-presenting capacity (de Waal-Malefyt et al. 1991)
andcytokineproduction (Fiorentino etal. 1991). 11-10 inhibits IFN-
yandTNF-aproduction by lymphokine-activated killer(LAK) cells
(Spagnoli et al. 1993). Production of IL-10 by lung cancer cells has
beenreported (Smith etal. 1994; Hung etal. 1995). Moreover. Hung
et al (1996) have reported that prostaglandin E, and other soluble
mediators producedby lung cancercells induce IL-10production by
blood lymphocytes and thus inhibit cell-mediated anti-tumour
immune responses. 11-15. alone or in combination with IL-12, was
less effective in inducing IL-10 production by MNCs from lung
cancerpatientscompared with1L-2 (Figure 2) and. thus. lesserincli-
nation totype 2 dominance in thepresenceof IL-15 mayhaveather-
apeutic benefit in cancerimmunotherapy.
1L-5 is produced by 11-2-activated MNCs from cancer patients
in vivo and in vitro (Enokihara et al. 1989; Nakamura et al. 1990:
Schaafsman et al, 1991), and may cause marked eosinophilia and
extravascular eosinophil degradation (van-Haelst-Pisani et al.
1991). In line with these previous reports. we observed that MNCs
from lung cancer patients cultured with IL-2 alone or in combina-
tion with1L-12 produce significant amount of11-5 in vitro (Figure
2). In contrast, IL-15 alone, or in combination with IL-12, induced
no 11L-5 production by MNCs from lung cancer patients as well as
control subjects. On the other hand. IL-15-activated and IL-2-acti-
vated MNCs from lung cancerpatients showed nodifference in the
production of GM-CSF (Figure 2). another possible mediator of
systemic eosinophilia (Donahue et al, 1986; Schaafsman et al.
1991). These findings suggest that IL-15 therapy may cause less
eosinophilia and fewer side-effects than 11L-2 therapy. The mecha-
nism ofthis difference between the functions of 11L-2 and IL-15 is
unknown at present, but the difference in the distribution and role
of IL-1SR a-chain (Giri et al. 1995) and IL-2R a-chain may be
one plausible mechanism.
In summary. we found that 1L-15 and IL-2 induced similarkiller
activity against SBC-3 cells: however, compared with 1L-2. IL-15
induced production of type 2 cytokines to a much lesser extent.
Further studies. such as analysis ofthe distribution and role ofthe
IL-lSRa-chain in comparison with those of the IL-2Ra-chain in
lung cancer patients. are necessary to clarify the potential role of
IL-15 in cancer immunotherapy in humans.
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